La carte de la Cosmetic Valley

HCS Pharma is now member of the Cosmetic Valley competitiveness cluster, the worldwide leader in perfumery and cosmetics resources, skills, research and training.

Cosmetic Valley was designated a “competitiveness cluster” by the Inter-ministerial Committee for the Development and Competitiveness of Regions (CIACT) on July 12, 2005. Today it is the worldwide leader in perfumery cosmetics resources and contributes to the development of the perfumery cosmetics sector with more then 800 companies for approximately 70,000 jobs and €11 billion in revenue !

With the backing of local authorities, Cosmetic Valley leads a network of businesses and research and training centres committed to a joint approach based on a dynamic focused on innovation.

HCS Pharma is really happy to be now part of this cluster, as our dermocosmetology services are focused on innovation and new efficient technologies (like HCS). It’s a pleasure to meet and talk with researchers of the cosmetology field.

After having been eclipsed by Target-Based Screening, Phenotypic Screening is finally shining again

The Right Combination

“We take the idea of using drug combinations to treat a disease and apply it to the phenotypic screen. In our particular case, we have successfully employed this approach to multidrug-resistant bacteria and the Ebola virus,” expounds Wei Zheng, Ph.D., a group leader at the National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH).

Thinking Inside the Black Box

“Remember the ‘Rule of 3’ for phenotypic screens,” urges Dr. Hett. This rule refers to the right cells, the right stimulus, and the right readout. The better the disease is understood, Dr. Hett adds, the better the model system that can be constructed.

Source :

The pharmaceutical industry is in upheaval. Since 20 years, inefficiency of pharmaceutical industry to turn its discoveries into new drugs force them to change their model. After target-based screening, they come back to phenotypic screening by high content screening and by using more relevant models as 3D cell models. In the same time, they share their tools, their expertise and now their chemical libraries with academic research labs and even with competitors to collaborate with them. Nice example of open innovation are with Sanofi and Astrazeneca. The Sanofi site in Straboug was become an open access innovation patform since 2014 and they are involved in public-private & French-German partnering called Ksilink project.  In the same time, Astrazeneca performed the same thing in Cambridge UK. Whereas before the chemical librairies represented the treasure of each pharmaceutical industry, now the mind change and the model is to exchange chemical librairies. AstraZeneca has recently made agreements with Sanofi and Syngenta to exchange 240,000 novel compounds for screening at no cost. Another model of compound sharing is the collaboration between AstraZeneca and Bayer, whereby each company makes available its entire compound library for screening of the partner’s target.

The success to find new drugs is in open innovation and partnerhip?

Full article “Toward a hit for every target” from AstraZeneca :

News on this article: 

We will be present in the “innovation zone” during the Drug discovery 2015 in Telford the 2nd and 3rd of September. The event is organised by ELRIG into 8 scientific sessions, which one is on phenotypic discovery and cell imaging. For participants, this event is free of charge. Thus, come and see us in the innovation zone!
If you want more detail about this event, follow this link:

%d bloggers like this: